Blackhorse. No it isn't. Grow up. |
Money moving to APH |
Quite a spread of views!
It is important to bear in mind what a commentator's price target means: it is not 'current fair value', but (unless otherwise stated) a price which the commentator at present believes will be hit at some time within the following 12 months, and not necessarily sustained thereafter, still less that there will not be further rises /falls from the price at the date on which the target was stated before that figure is hit, if indeed it is hit. |
Stifel cuts AstraZeneca price target to 12,000 (12,550) pence - 'buy'
Barclays cuts AstraZeneca price target to 12,500 (13,500) pence - 'overweigh
UBS cuts AstraZeneca price target to 9,900 (10,700) pence - 'sell' |
Deutsche Bank cuts AstraZeneca to 'sell' (hold) - price target 9,500 (11,000) pence |
Rebounding in the US listing |
"Beckers2008 - 31 Mar 2022 - 14:48:08 - 5532 of 5974
I'm out at £102. This is above quite a few broker PT's so happy to take profits.
Currently way above 20 mda, too high too quickly, will buy back when it settles.
Good Luck all."
Should have held for a while longer, but you live and learn.
GLA. |
AZN is still pretty richly priced. I think it should slide a bit more. I may put a limit order in to buy a few more at 93, though that will significantly above my average, currently 58 after a few out and back in round trips a few years back.
AZN does not pay much of a dividend, and I see no catalyst to move the price north at present, so in this uncertain market I shall probably put in my order at 90 and be patient. |
Should has stated, dipped in at £97.70.7 |
I've been waiting patiently and finally been able to buy back in here, after a few years.
SP reaction,overdone today, hopefully luckily for me? Let's wait and see. |
‘Many investors view AstraZeneca as invincible given its success in recent years, yet its latest results showed that even the mighty can disappoint. The drugs giant missed fourth quarter earnings expectations due to more money being spent on research and development and a greater contribution from lower-margin sales in emerging markets. However, the business remains optimistic about the prospects for its cancer and rare disease drugs,’ AJ Bell analyst Russ Mould commented. |
Poor divi in present 5% money market funds environment. Great company but well heeled managers, along with scores of other companies paying 2-3% need to get real. The boards of these businesses don't give a f..k about shareholders-they are so well paid in any case. No recovery here until rates drop to 3% |
Yep the yanks pushing this further down |
Just topped up, I read that the fall relates to them missing Q4 projections, just, but against the 2024-5 forecast and rest of year it seems overdone |
seems a heavy fall on results that weren't that bad. took a small position to start |
Looks well overdone to me. IMO it will recover |
Me too.
Suet |
Yeh just had a nibble at 98, then waiting for US to open and see.. |
Can't be far off now, surely.
Might have another little plummet when stateside opens. |
Ouch, what's the bottom here u think.. |
vaston. Grow up. |
SYME IS NOW READY TO FLY |
Continues to disappoint. |
Dounbtless if profits halved market would raise price by £2.50 |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
